Association between genetic polymorphisms of drug-metabolizingenzymes and factors of liver cancer

本研究旨在阐明药物代谢酶CYP2C19基因突变与肝癌易感性的关系。21例接受部分肝切除的日本肝癌患者的肝脏和血液样本均为捐献。结果表明，转移性肝癌患者中发现的基因突变是先天的，而不是发生在肿瘤周围，所有样本中的细胞色素P450 2 C19活性均降低，其程度与多种细胞因子的变化有关，但与酶的基因型无关。为了预防转移和正确治疗肝癌，还需要进一步的研究来阐明所获得的结果的机制和意义，并阐明CYP2C19在癌症患者中的作用。

This study was conducted to clarify the association between drug-metabolizing enzyme CYP2C19 gene mutation and liver cancer susceptibility. 21 liver and blood samples were donated from Japanese liver cancer patients who received partial hepatectomy. The results indicated that the gene mutation found in high frequency in metastatic liver cancer patients occur congenitally rather than arise in peripheral tumor site acquired by cancer condition.CYP2C19 activity decreased in all samples and the degree was associated with changes in several cytokines, but did not correlate with the genotype of the enzyme. For the prevention of metastasis and for the proper treatment of liver cancer, further studies elucidating the mechanisms and significance of the results obtained and clarifying the role of CYP2C19 in cancer patients are needed.